391 related articles for article (PubMed ID: 33655663)
1. Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection.
Alkrekshi A; Tamaskar I
Oncologist; 2021 May; 26(5):e827-e830. PubMed ID: 33655663
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.
Pertejo-Fernandez A; Ricciuti B; Hammond SP; Marty FM; Recondo G; Rangachari D; Costa DB; Awad MM
Lung Cancer; 2020 Jul; 145():181-185. PubMed ID: 32423643
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.
Pu D; Yin L; Zhou Y; Li W; Huang L; Cai L; Zhou Q
Medicine (Baltimore); 2020 Jan; 99(5):e19013. PubMed ID: 32000444
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage.
Fukuda R; Sugawara S; Kondo Y
Intern Med; 2020 Sep; 59(18):2245-2248. PubMed ID: 32522918
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.
Shah NJ; Al-Shbool G; Blackburn M; Cook M; Belouali A; Liu SV; Madhavan S; He AR; Atkins MB; Gibney GT; Kim C
J Immunother Cancer; 2019 Dec; 7(1):353. PubMed ID: 31847881
[TBL] [Abstract][Full Text] [Related]
6. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
7. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
[TBL] [Abstract][Full Text] [Related]
8. Infectious complications of immune checkpoint inhibitors in solid organ malignancies.
Ross JA; Komoda K; Pal S; Dickter J; Salgia R; Dadwal S
Cancer Med; 2022 Jan; 11(1):21-27. PubMed ID: 34873868
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
[TBL] [Abstract][Full Text] [Related]
10. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
11. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
Horiuchi K; Ikemura S; Sato T; Shimozaki K; Okamori S; Yamada Y; Yokoyama Y; Hashimoto M; Jinzaki M; Hirai I; Funakoshi T; Mizuno R; Oya M; Hirata K; Hamamoto Y; Terai H; Yasuda H; Kawada I; Soejima K; Fukunaga K
Oncologist; 2024 Jan; 29(1):e108-e117. PubMed ID: 37590388
[TBL] [Abstract][Full Text] [Related]
12. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
Rahma OE; Reuss JE; Giobbie-Hurder A; Shoja E Razavi G; Abu-Shawer O; Mehra P; Gupta S; Simon R; Khleif SN
Clin Cancer Res; 2021 Jan; 27(2):485-491. PubMed ID: 33082209
[TBL] [Abstract][Full Text] [Related]
13. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
[No Abstract] [Full Text] [Related]
14. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors.
Yibirin M; Mustafayev K; Hosry J; Pundhir P; Klingen J; Yepez Guevara E; Granwehr BP; Kaseb A; Naing A; Patel S; Shah AY; Skoulidis F; Tawbi HA; Wang L; Miller E; Zhang HC; Zurita-Saavedra A; Torres HA
Am J Gastroenterol; 2023 Sep; 118(9):1609-1617. PubMed ID: 37307533
[TBL] [Abstract][Full Text] [Related]
16. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence.
Byeon S; Cho JH; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Med; 2020 Apr; 9(7):2352-2362. PubMed ID: 32027780
[TBL] [Abstract][Full Text] [Related]
17. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
Kothapalli A; Khattak MA
Melanoma Res; 2018 Apr; 28(2):155-158. PubMed ID: 29406396
[TBL] [Abstract][Full Text] [Related]
19. Management of autoimmune and viral hepatitis in immunotherapy: a narrative review.
Kuo L; Kuwelker S; Tsai E
Ann Palliat Med; 2023 Nov; 12(6):1275-1294. PubMed ID: 37731304
[TBL] [Abstract][Full Text] [Related]
20. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
